North Andover, Mass
achusetts, USA
(February
10
, 2013)
–
During the February 2, 2013 Meeting
of the Board of Directors of
Bach
Pharma, Inc. held in Durham, North Carolina
,
Chairman of the Board
Dr. Steven L. Stroup
announced
the appointment of
Dr. William S. Lynn
of
Hillsboro
, North Carolina
to
the
first ever
position of
Director Emeritus for the Company.
Dr. Lynn has held
the positions of
Director, Vice President and Director of Science
for Bach Pharma for the past 12
years.
He continues
to oversee the planning, design and reporting of
all of Bach’s research and intellectual property.
Dr.
Lynn is a
recognized
thought
leader
in
clinical
research,
with special emphasis
in the
areas
of oxidative
stress
, inflammation, metabolism, neurodegeneration and the central nervous system
. Dr. Lynn has
written over 130 publications and books, and coined the term of his book titled “Neuroimmuno
-
degeneration”
with co
-
writer
Dr. Paul K.Y. Wong in 1998.

Dr. Lynn received his undergraduate training
in Alabama
at Auburn University
,
and his MD degree at
Colum
bia University
in New York
. He
completed his
post
doctoral
fellowships
at
the University of
Pennsylvania
and Duke University
.
A Markle Scholar at Duke University, Dr. Lynn
went on to become
Professor of Me
dicine and Associate Professor of Biochemistry
, whe
re he
became
a lifelong
enthusiastic
fan of Duke
Basketball
.
In 1992, a
fter holding professorial positions at The University of
Texas, Galveston, Departments of Internal Medicine and Human Nutrition,
Dr. Lynn
continued on to
his current
position of
Visitin
g Scientist at the University of Texas, MD Anderson Cancer Center
in
Smithville, Texas.

Dr. Lynn has been a
Clinical Research Physician at Cato Res
earch in Durham, North Carolina since
1992, where he is responsible for managing the design, protocols, dir
ection and interpretation of
clinical
trials and research from Phase 1
through Phase
4
of products under development. He has also
coordinated reporting information to the FDA on adverse events and safety monitoring.

In his remarks to Dr. Lynn on the prese
ntation of this award, Bach Pharma CEO, Mark O. Henry,
detailed Dr. Lynn’s remarkable history and praised his work and integrity. “There is no one who knows
more about oxidative stress in the human body,” he said. “Dr. Lynn’s knowledge has undoubtedly
plac
ed Bach Pharma in a leadership role in developing treatment for all manners of illness caused by
oxidative stress. We are truly thankful for his association with our company and present him this
award which confers a lifetime position on our Board of Direc
tors.”

About Bach Pharma

Bach Pharma, Inc.,
based in North Andover, MA is a pharmaceutical company engaged in the
discovery, development, and commercialization of new therapeutics for the treatment of life
threatening oxidative stress related diseases as
well as other serious illnesses. Bach is a member of
the US
-
Russian Chamber of Commerce of New England and pioneered the founding of the US
-
Russian
Scientific Exchange Forum. The Foundation for the National Institutes of Health (FNIH), in partnership
with
the National Institutes of Health (NIH), the Institute of Medicine (IOM) and the Russian Academy
of Sciences (RAS) of the Russian Federation, was created as a result of the 2009 U.S.
-
Russia Bi
-
Lateral Presidential Commission, which highlighted greater coo
peration in the health sciences as a key
theme. The Forum promote
s
and facilitate
s
broader research collaboration in the biomedical and
behavioral sciences between the U.S. and Russian scientific communities, with the goal of improving
public health. Speci
fically, the Forum will strengthen joint research activities related to disease control,
treatment and prevention, clinical
and translational research,
regulatory science, and the development
of new health technologies.

Incorporated in 2001,
Bach develope
d the proprietary manufacturing technologies for its proven
phthalazinedione drug platform, and
owns all of the intellectual property that encompasses this entire
class of phthalazinediones as pharmaceutical agents. Monosodium Luminol is a subclass of
phth
alazinediones. Bach maintains one of the world’s most active monosodium luminol research
programs focused on specific compound platforms and their derivates.

Bach is an enthusiastic member of the
MassBio Council
, Advancing Massachusetts Biotechnology fo
r
worldwide medical benefits, and a proud host company of
the
Massachusetts Life Sciences Center
Internship Challenge Program
.

About Cato Research Ltd

Cato Research is a contract research organization (CRO) providing a complete range of services
specializing in innovative development strategies for pharmaceutical and biotechnology companies
through all stages of the clinical development process.
Cato Research has
strategic
offices through
-
out
the world, including Tel Aviv,
Israel, Fourways, South
Africa, and Quebec, Canada. Cato Research is a
strategic alliance partner and CRO for Bach Pharma with offices
located in the Bay Colony Corporate
C
enter in Waltham, Massachusetts.

For more information about Cato Research companies please visit their
main website
www.cato.com
,
contact them by telephone 919.361.CATO (2286), or email
info@cato.com
.

For additional information about Bach Pharma please visit their website at
www.bachpharma.com
,
contact them by telephone 978.794.5510, or email
info@bachpharma.com
.